皮膚科治療薬の市場シェア、規模、動向、産業分析レポート：治療領域別、薬剤クラス別、投与経路別（局所、経口、非経口）、流通チャネル別、地域別、セグメント予測、2023～2032年

Polaris Market Researchの新しい調査によると、世界の皮膚科治療薬の市場規模は2032年までに504億7,000万米ドルに達すると予想されています。本レポートでは、現在の市場力学を詳細に把握し、将来の市場成長に関する分析を提供しています。

皮膚科治療薬市場は、有病率の上昇に伴い、世界的に皮膚科疾患の負担が増加していることから、需要が急増しています。疾患の進行や病因に対する認識が高まり、効果的な治療法への需要が高まっています。高齢者人口の増加は、市場の成長に大きく寄与しています。

高齢者は、加齢に伴うさまざまな生理的変化により、皮膚関連疾患にかかりやすくなっています。例えば、結合組織の変化、皮膚の強度と弾力性の低下、皮脂腺分泌の減少などは、高齢者によく見られる現象であり、皮膚科治療薬の需要増につながっています。

皮膚科は、皮膚、粘膜、毛髪、爪の障害や疾患を包括する多様な専門分野です。このカテゴリーの疾患には、にきび、多発性炎症性皮膚炎、皮膚がん、自己免疫疾患、職業性皮膚炎、接触性皮膚炎が含まれます。ニキビ、酒さ、乾癬、アトピー性皮膚炎などがあり、非常に細分化された治療領域です。

生物学的製剤は、その有効性と標的を絞ったアプローチから、皮膚科疾患の治療オプションとして普及しており、多くの医薬品が規制当局から承認され、さらに多くの医薬品が開発中です。また、患者は利便性、副作用の少なさ、標的へのアプローチから、全身薬よりも局所的な治療を好むようになっており、皮膚科用局所薬の需要増につながっています。新興市場での需要の高まり、併用療法の採用の増加、個別化医療への注力も、業界の成長を後押ししています。

例えば、2022年3月、ジョンソン・エンド・ジョンソンのヤンセンファーマシューティカルカンパニーズは、中等度から重度の尋常性乾癬および/または頭皮乾癬に苦しむ有色人種を対象に、薬の安全性と有効性を評価するVISIBLEと名付けられた前向き臨床試験を開始しました。

皮膚科治療薬市場レポートハイライト

• 乾癬分野は、世界的に乾癬の有病率が高まっていること、およびメーカーが治療薬を発売していることから、最大の市場シェアを占めています。
• コルチコステロイドは、乾癬、皮膚炎、にきびなど、さまざまな皮膚疾患の症状において広く使用されています。
• 非経口剤が市場で最も大きなシェアを占めているのは、皮膚疾患に対して様々な生物学的製剤が利用可能であり、生物学的製剤は一般的に非経口投与経路で服用されるからです。
• 病院薬局部門が市場を独占しており、予測期間中もその支配は続くと思われます。現代人は皮膚病に対する意識が高く、そのため病院を訪れる患者が増加し、処方箋薬の売上が増加しています。
• 北米が最大の市場シェアを占めており、予測期間中もその優位性を維持すると予想されます。皮膚疾患に対する認識が高まり、治療法が確立されたこと、主な企業がこの市場を開拓していることが、この地域の成長を後押ししています。
• 世界の主要な市場企業：Lupin、Novartis AG、F. Hoffmann-La Roche Ltd、Pfizer Inc、Sanofi、Amgen Inc、Lilly、AstraZeneca、AbbVie Inc、Johnson &Johnson Private Limited、LEO Pharma A/S, Merck &Co.Inc.、Bausch Health Companies Inc.、Bristol-Myers Squibb Company

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の皮膚科治療薬市場に関する洞察

• 皮膚科治療薬-業界スナップショット
• 皮膚科治療薬市場力学
  • 促進要因と機会
    • 高齢者人口の増加
    • 臨床研究の増加
  • 抑制要因と課題
    • 高コスト
• PESTLE分析
• 皮膚科治療薬業界の動向
• バリューチェーン分析
• COVID-19感染症の影響分析

第5章 世界の皮膚科治療薬市場、治療領域別

• 主な調査結果
• イントロダクション
• ニキビ
• アトピー性皮膚炎
• 乾癬
• 酒さ様皮膚炎
• その他

第6章 世界の皮膚科治療薬市場、薬剤クラス別

• 主な調査結果
• イントロダクション
• 抗感染症薬
• コルチコステロイド
• ニキビ対策
• カルシニューリン阻害薬
• レチノイド
• その他

第7章 世界の皮膚科治療薬市場、投与経路別

• 主な調査結果
• イントロダクション
• 局所
• 経口
• 非経口

第8章 世界の皮膚科治療薬市場、流通チャネル別

• 主な調査結果
• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界の皮膚科治療薬市場、地域別

• 主な調査結果
• イントロダクション
  • 皮膚科治療薬市場評価、地域別、2019-2032年
• 皮膚科治療薬市場-北米
  • 北米：皮膚科治療薬市場、治療領域別、2019-2032年
  • 北米：皮膚科治療薬市場、流通チャネル別、2019-2032年
  • 北米：皮膚科治療薬市場、薬剤クラス別、2019-2032年
  • 北米：皮膚科治療薬市場、投与経路別、2019-2032年
  • 皮膚科治療薬市場- 米国
  • 皮膚科治療薬市場- カナダ
• 皮膚科治療薬市場- 欧州
  • 欧州：皮膚科治療薬市場、治療領域別、2019～2032年
  • 欧州：皮膚科治療薬市場、流通チャネル別、2019～2032年
  • 欧州：皮膚科治療薬市場、薬剤クラス別、2019～2032年
  • 欧州：皮膚科治療薬市場、投与経路別、2019～2032年
  • 皮膚科治療薬市場- 英国
  • 皮膚科治療薬市場- フランス
  • 皮膚科治療薬市場- ドイツ
  • 皮膚科治療薬市場- イタリア
  • 皮膚科治療薬市場- スペイン
  • 皮膚科治療薬市場- オランダ
  • 皮膚科治療薬市場- ロシア
• 皮膚科治療薬市場- アジア太平洋
  • アジア太平洋地域：皮膚科治療薬市場、治療分野別、2019～2032年
  • アジア太平洋地域：皮膚科治療薬市場、流通チャネル別、2019～2032年
  • アジア太平洋地域：皮膚科治療薬市場、薬剤クラス別、2019～2032年
  • アジア太平洋地域：皮膚科治療薬市場、投与経路別、2019～2032年
  • 皮膚科治療薬市場- 中国
  • 皮膚科治療薬市場- インド
  • 皮膚科治療薬市場- 日本
  • 皮膚科治療薬市場- マレーシア
  • 皮膚科治療薬市場- インドネシア
  • 皮膚科治療薬市場- 韓国
• 皮膚科治療薬市場-中東・アフリカ
  • 中東・アフリカ：皮膚科治療薬市場、治療領域別、2019～2032年
  • 中東・アフリカ：皮膚科治療薬市場、流通チャネル別、2019-2032年
  • 中東・アフリカ：皮膚科治療薬市場、薬剤クラス別、2019～2032年
  • 中東・アフリカ：皮膚科治療薬市場、投与経路別、2019～2032年
  • 皮膚科治療薬市場- サウジアラビア
  • 皮膚科治療薬市場- 南アフリカ
  • 皮膚科治療薬市場- イスラエル
  • 皮膚科治療薬市場- アラブ首長国連邦
• 皮膚科治療薬市場-ラテンアメリカ
  • ラテンアメリカ：皮膚科治療薬市場、治療領域別、2019-2032年
  • ラテンアメリカ：皮膚科治療薬市場、流通チャネル別、2019-2032年
  • ラテンアメリカ：皮膚科治療薬市場、薬剤クラス別、2019-2032年
  • ラテンアメリカ：皮膚科治療薬市場、投与経路別、2019-2032年
  • 皮膚科治療薬市場- メキシコ
  • 皮膚科治療薬市場- ブラジル
  • 皮膚科治療薬市場- アルゼンチン

第10章 競合情勢

• 拡張と買収の分析
  • 拡張
  • 買収
• パートナーシップ/コラボレーション/協定/公開

第11章 企業プロファイル

• Lupin
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi
• Amgen Inc
• Lilly
• AstraZeneca
• AbbVie Inc.
• Johnson & Johnson Private Limited
• LEO Pharma A/S
• Merck & Co. Inc
• Bausch Health Companies Inc
• Bristol-Myers Squibb Company

List of Tables

• Table 1 Global Dermatology Drugs Market, by Therapeutic Area, by Region, 2019-2032 (USD Billion)
• Table 2 Global Dermatology Drugs Market, by Drug Class, by Region, 2019-2032 (USD Billion)
• Table 3 Global Dermatology Drugs Market, by Route of Administration, by Region, 2019-2032 (USD Billion)
• Table 4 Global Dermatology Drugs Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
• Table 5 Dermatology Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
• Table 6 North America: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 7 North America: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 8 North America: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 9 North America: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 10 U.S.: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 11 U.S.: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 12 U.S.: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 13 U.S.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 14 Canada: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 15 Canada: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 16 Canada: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 17 Canada: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 18 Europe: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 19 Europe: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 20 Europe: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 21 Europe: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 22 Germany: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 23 Germany: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 24 Germany: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 25 Germany: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 26 France: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 27 France: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 28 France: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 29 France: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 30 UK: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 31 UK: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 32 UK: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 33 UK: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 34 Italy: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 35 Italy: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 36 Italy: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 37 Italy: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 38 Netherlands: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 39 Netherlands: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 40 Netherlands: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 41 Netherlands: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 42 Spain: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 43 Spain: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 44 Spain: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 45 Spain: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 46 Russia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 47 Russia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 48 Russia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 49 Russia: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 50 Asia Pacific: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 51 Asia Pacific: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 52 Asia Pacific: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 53 Asia Pacific: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 54 China: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 55 China: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 56 China: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 57 China: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 58 Japan: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 59 Japan: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 60 Japan: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 61 Japan: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 62 India: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 63 India: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 64 India: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 65 India: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 66 Indonesia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 67 Indonesia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 68 Indonesia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 69 Indonesia: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 70 Malaysia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 71 Malaysia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 72 Malaysia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 73 Malaysia: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 74 South Korea: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 75 South Korea: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 76 South Korea: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 77 South Korea: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 78 Latin America: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 79 Latin America: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 80 Latin America: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 81 Latin America: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 82 Brazil: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 83 Brazil: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 84 Brazil: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 85 Brazil: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 86 Mexico: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 87 Mexico: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 88 Mexico: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 89 Mexico: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 90 Argentina: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 91 Argentina: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 92 Argentina: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 93 Argentina: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 94 Middle East & Africa: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 95 Middle East & Africa: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 96 Middle East & Africa: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 97 Middle East & Africa: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 98 UAE: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 99 UAE: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 100 UAE: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 101 UAE: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 102 Saudi Arabia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 103 Saudi Arabia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 104 Saudi Arabia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 105 Saudi Arabia: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 106 South Africa: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 107 South Africa: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 108 South Africa: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 109 South Africa: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• Table 110 Israel: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• Table 111 Israel: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• Table 112 Israel: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• Table 113 Israel: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

• Figure 1. Global Dermatology Drugs Market, 2019-2032 (USD Billion)
• Figure 2. Integrated Ecosystem
• Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
• Figure 4. Market by Geography
• Figure 5. Porter's Five Forces
• Figure 6. Market by Therapeutic Area
• Figure 7. Global Dermatology Drugs Market, by Therapeutic Area, 2021 & 2030 (USD Billion)
• Figure 8. Market by Distribution Channel
• Figure 9. Global Dermatology Drugs Market, by Distribution Channel, 2021 & 2030 (USD Billion)
• Figure 10. Market by Drug Class
• Figure 11. Global Dermatology Drugs Market, by Drug Class, 2021 & 2030 (USD Billion)
• Figure 12. Market by Route of Administration
• Figure 13. Global Dermatology Drugs Market, by Route of Administration, 2021 & 2030 (USD Billion)

The global dermatology drugs market size is expected to reach USD 50.47 billion by 2032, according to a new study by Polaris Market Research. The report "Dermatology Drugs Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Drug Class; By Route of Administration (Topical, Oral, Parenteral); By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The dermatology drugs market is experiencing a surge in demand due to a growing burden of dermatology diseases globally, with increasing prevalence rates. Increased awareness of disease progression and etiology has increased, leading to a higher demand for effective treatments. The rise in the elderly population has contributed significantly to the market's growth.

Older individuals are more susceptible to skin-related disorders due to various physiological changes associated with aging. For instance, changes in the connective tissue, reduction in skin strength and elasticity, and decrease in sebaceous gland secretions are common in aging individuals, leading to a higher demand for dermatology drugs.

Dermatology is a diverse specialty encompassing disorders and diseases of the skin, mucous membrane, hair, and nails. Conditions in this category include acne, multiple inflammatory dermatoses, skin cancers, autoimmune disease, occupational dermatitis, and contact dermatitis. It's a highly fragmented therapeutic area, under which comes acne, rosacea, psoriasis, atopic dermatitis, and other disorders.

Biologics are becoming a popular treatment option for dermatological conditions due to their effectiveness and targeted approach, with many drugs approved by regulatory bodies and more in development. Patients also increasingly prefer topical treatments over systemic medications due to convenience, fewer side effects, and targeted approach, leading to a rise in the demand for topical dermatology drugs. The rising demand in emerging markets, increasing adoption of combination therapies, and focus on personalized medicine are also driving growth in the industry.

For instance, In March 2022, Johnson & Johnson's Janssen Pharmaceutical Companies initiated a prospective clinical trial named VISIBLE to evaluate the safety and efficacy of a drug for people of color suffering from moderate to severe plaque and/or scalp psoriasis.

Dermatology Drugs Market Report Highlights

• Psoriasis segment is accounted for the largest market share because of the increasing the prevalence of psoriasis globally and manufacturers launching new medications for the treatment.

• Corticosteroids segment holds the highest CAGR of the market. in various conditions of skin disorders topical corticosteroids are used widely in conditions such as psoriasis, dermatitis, acne and others.

• parenteral segment holds the largest share in the market, due to various biologics are available for the dermatological conditions, and biologics are generally taken through the parenteral route of administration.

• Hospital pharmacy segment dominated the market and willing to continue its dominance over the forecast period. Nowadays peoples are aware with the skin diseases that's why increased in the patient visits to hospitals and sales of prescription drugs increased.

• North America holds the largest market share in the market and expected to maintain its dominance during the forecast period. Increased in the awareness of skin diseases and raising the treatment and key players making the developments in this market fuels the growth of the region.

• The global key market players include: Lupin, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi, Amgen Inc., Lilly, AstraZeneca, AbbVie Inc., Johnson & Johnson Private Limited, LEO Pharma A/S, Merck & Co. Inc., Bausch Health Companies Inc., and Bristol-Myers Squibb Company.

Polaris Market Research has segmented the dermatology drugs market report based on therapeutic area, drug class, route of administration, distribution channel, and region:

Dermatology Drugs, Therapeutic Area Outlook (Revenue - USD Billion, 2019 - 2032)

• Acne
• Atopic Dermatitis
• Psoriasis
• Rosacea
• Others

Dermatology Drugs, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

• Anti-infectives
• Corticosteroids
• Anti-acne
• Calcineurin Inhibitors
• Retinoids
• Others

Dermatology Drugs, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

• Topical
• Oral
• Parenteral

Dermatology Drugs, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Dermatology Drugs, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia
• Latin America
• Argentina
• Brazil
• Mexico
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Dermatology Drugs Market Insights

• 4.1. Dermatology Drugs - Industry Snapshot
• 4.2. Dermatology Drugs Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing Elderly Population
    • 4.2.1.2. Rise in Clinical Studies
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Cost
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Dermatology Drugs Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Dermatology Drugs Market, by Therapeutic Area

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
• 5.3. Acne
  • 5.3.1. Global Dermatology Drugs Market, by Acne, by Region, 2019-2032 (USD Billion)
• 5.4. Atopic Dermatitis
  • 5.4.1. Global Dermatology Drugs Market, by Atopic Dermatitis, by Region, 2019-2032 (USD Billion)
• 5.5. Psoriasis
  • 5.5.1. Global Dermatology Drugs Market, by Psoriasis, by Region, 2019-2032 (USD Billion)
• 5.6. Rosacea
  • 5.6.1. Global Dermatology Drugs Market, by Rosacea, by Region, 2019-2032 (USD Billion)
• 5.7. Others
  • 5.7.1. Global Dermatology Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Dermatology Drugs Market, by Drug Class

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
• 6.3. Anti-infectives
  • 6.3.1. Global Dermatology Drugs Market, by Anti-infectives, by Region, 2019-2032 (USD Billion)
• 6.4. Corticosteroids
  • 6.4.1. Global Dermatology Drugs Market, by Corticosteroids, by Region, 2019-2032 (USD Billion)
• 6.5. Anti-acne
  • 6.5.1. Global Dermatology Drugs Market, by Anti-acne, by Region, 2019-2032 (USD Billion)
• 6.6. Calcineurin Inhibitors
  • 6.6.1. Global Dermatology Drugs Market, by Calcineurin Inhibitors, by Region, 2019-2032 (USD Billion)
• 6.7. Retinoids
  • 6.7.1. Global Dermatology Drugs Market, by Retinoids, by Region, 2019-2032 (USD Billion)
• 6.8. Others
  • 6.8.1. Global Dermatology Drugs Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Dermatology Drugs Market, by Route of Administration

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• 7.3. Topical
  • 7.3.1. Global Dermatology Drugs Market, by Topical, by Region, 2019-2032 (USD Billion)
• 7.4. Oral
  • 7.4.1. Global Dermatology Drugs Market, by Oral, by Region, 2019-2032 (USD Billion)
• 7.5. Parenteral
  • 7.5.1. Global Dermatology Drugs Market, by Parenteral, by Region, 2019-2032 (USD Billion)

8. Global Dermatology Drugs Market, by Distribution Channel

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
• 8.3. Hospital Pharmacy
  • 8.3.1. Global Dermatology Drugs Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
• 8.4. Retail Pharmacy
  • 8.4.1. Global Dermatology Drugs Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)
• 8.5. Online Pharmacy
  • 8.5.1. Global Dermatology Drugs Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)

9. Global Dermatology Drugs Market, by Geography

• 9.1. Key findings
• 9.2. Introduction
  • 9.2.1. Dermatology Drugs Market Assessment, By Geography, 2019-2032 (USD Billion)
• 9.3. Dermatology Drugs Market - North America
  • 9.3.1. North America: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 9.3.2. North America: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.3.3. North America: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.3.4. North America: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.3.5. Dermatology Drugs Market - U.S.
    • 9.3.5.1. U.S.: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.3.5.2. U.S.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.5.3. U.S.: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.5.4. U.S.: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.3.6. Dermatology Drugs Market - Canada
    • 9.3.6.1. Canada: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.3.6.2. Canada: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.6.3. Canada: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.6.4. Canada: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• 9.4. Dermatology Drugs Market - Europe
  • 9.4.1. Europe: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 9.4.2. Europe: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.4.3. Europe: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.4.4. Europe: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.5. Dermatology Drugs Market - UK
    • 9.4.5.1. UK: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.5.2. UK: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.5.3. UK: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.5.4. UK: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.6. Dermatology Drugs Market - France
    • 9.4.6.1. France: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.6.2. France: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.6.3. France: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.6.4. France: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.7. Dermatology Drugs Market - Germany
    • 9.4.7.1. Germany: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.7.2. Germany: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.7.3. Germany: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.7.4. Germany: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.8. Dermatology Drugs Market - Italy
    • 9.4.8.1. Italy: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.8.2. Italy: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.8.3. Italy: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.8.4. Italy: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.9. Dermatology Drugs Market - Spain
    • 9.4.9.1. Spain: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.9.2. Spain: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.9.3. Spain: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.9.4. Spain: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.10. Dermatology Drugs Market - Netherlands
    • 9.4.10.1. Netherlands: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.10.2. Netherlands: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.10.3. Netherlands: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.10.4. Netherlands: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4.11. Dermatology Drugs Market - Russia
    • 9.4.11.1. Russia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.4.11.2. Russia.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.11.3. Russia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.11.4. Russia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• 9.5. Dermatology Drugs Market - Asia Pacific
  • 9.5.1. Asia Pacific: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 9.5.2. Asia Pacific: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.5.3. Asia Pacific: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.5.4. Asia Pacific: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.5. Dermatology Drugs Market - China
    • 9.5.5.1. China: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.5.5.2. China.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.5.3. China: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.5.4. China: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.6. Dermatology Drugs Market - India
    • 9.5.6.1. India: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.5.6.2. India.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.6.3. India: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.6.4. India: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.7. Dermatology Drugs Market - Japan
    • 9.5.7.1. Japan: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.5.7.2. Japan.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.7.3. Japan: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.7.4. Japan: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.8. Dermatology Drugs Market - Malaysia
    • 9.5.8.1. Malaysia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.5.8.2. Malaysia.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.8.3. Malaysia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.8.4. Malaysia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.9. Dermatology Drugs Market - Indonesia
    • 9.5.9.1. Indonesia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.5.9.2. Indonesia.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.9.3. Indonesia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.9.4. Indonesia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5.10. Dermatology Drugs Market - South Korea
    • 9.5.10.1. South Korea: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.5.10.2. South Korea.: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.10.3. South Korea: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.10.4. South Korea: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• 9.6. Dermatology Drugs Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 9.6.2. Middle East & Africa: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.6.3. Middle East & Africa: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.6.4. Middle East & Africa: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6.5. Dermatology Drugs Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6.6. Dermatology Drugs Market - South Africa
    • 9.6.6.1. South Africa: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.6.6.2. South Africa: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.6.3. South Africa: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.6.4. South Africa: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6.7. Dermatology Drugs Market - Israel
    • 9.6.7.1. Israel: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.6.7.2. Israel: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.7.3. Israel: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.7.4. Israel: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6.8. Dermatology Drugs Market - UAE
    • 9.6.8.1. UAE: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.6.8.2. UAE: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.8.3. UAE: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.8.4. UAE: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
• 9.7. Dermatology Drugs Market - Latin America
  • 9.7.1. Latin America: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 9.7.2. Latin America: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 9.7.3. Latin America: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.7.4. Latin America: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7.5. Dermatology Drugs Market - Mexico
    • 9.7.5.1. Mexico: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.7.5.2. Mexico: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.5.3. Mexico: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.5.4. Mexico: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7.6. Dermatology Drugs Market - Brazil
    • 9.7.6.1. Brazil: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.7.6.2. Brazil: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.6.3. Brazil: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.6.4. Brazil: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7.7. Dermatology Drugs Market - Argentina
    • 9.7.7.1. Argentina: Dermatology Drugs Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 9.7.7.2. Argentina: Dermatology Drugs Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.7.3. Argentina: Dermatology Drugs Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.7.4. Argentina: Dermatology Drugs Market, by Route of Administration, 2019-2032 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Lupin
  • 11.1.1. Company Overview
  • 11.1.2. Financial PerRoute of Administrationance
  • 11.1.3. Distribution Channel Benchmarking
  • 11.1.4. Recent Development
• 11.2. Novartis AG
  • 11.2.1. Company Overview
  • 11.2.2. Financial PerRoute of Administrationance
  • 11.2.3. Distribution Channel Benchmarking
  • 11.2.4. Recent Development
• 11.3. F. Hoffmann-La Roche Ltd
  • 11.3.1. Company Overview
  • 11.3.2. Financial PerRoute of Administrationance
  • 11.3.3. Distribution Channel Benchmarking
  • 11.3.4. Recent Development
• 11.4. Pfizer Inc
  • 11.4.1. Company Overview
  • 11.4.2. Financial PerRoute of Administrationance
  • 11.4.3. Distribution Channel Benchmarking
  • 11.4.4. Recent Development
• 11.5. Sanofi
  • 11.5.1. Company Overview
  • 11.5.2. Financial PerRoute of Administrationance
  • 11.5.3. Distribution Channel Benchmarking
  • 11.5.4. Recent Development
• 11.6. Amgen Inc
  • 11.6.1. Company Overview
  • 11.6.2. Financial PerRoute of Administrationance
  • 11.6.3. Distribution Channel Benchmarking
  • 11.6.4. Recent Development
• 11.7. Lilly
  • 11.7.1. Company Overview
  • 11.7.2. Financial PerRoute of Administrationance
  • 11.7.3. Distribution Channel Benchmarking
  • 11.7.4. Recent Development
• 11.8. AstraZeneca
  • 11.8.1. Company Overview
  • 11.8.2. Financial PerRoute of Administrationance
  • 11.8.3. Distribution Channel Benchmarking
  • 11.8.4. Recent Development
• 11.9. AbbVie Inc.
  • 11.9.1. Company Overview
  • 11.9.2. Financial PerRoute of Administrationance
  • 11.9.3. Distribution Channel Benchmarking
  • 11.9.4. Recent Development
• 11.10. Johnson & Johnson Private Limited
  • 11.10.1. Company Overview
  • 11.10.2. Financial PerRoute of Administrationance
  • 11.10.3. Distribution Channel Benchmarking
  • 11.10.4. Recent Development
• 11.11. LEO Pharma A/S
  • 11.11.1. Company Overview
  • 11.11.2. Financial PerRoute of Administrationance
  • 11.11.3. Distribution Channel Benchmarking
  • 11.11.4. Recent Development
• 11.12. Merck & Co. Inc
  • 11.12.1. Company Overview
  • 11.12.2. Financial PerRoute of Administrationance
  • 11.12.3. Distribution Channel Benchmarking
  • 11.12.4. Recent Development
• 11.13. Bausch Health Companies Inc
  • 11.13.1. Company Overview
  • 11.13.2. Financial PerRoute of Administrationance
  • 11.13.3. Distribution Channel Benchmarking
  • 11.13.4. Recent Development
• 11.14. Bristol-Myers Squibb Company
  • 11.14.1. Company Overview
  • 11.14.2. Financial PerRoute of Administrationance
  • 11.14.3. Distribution Channel Benchmarking
  • 11.14.4. Recent Development